Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in:  The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind — BOSTON ( TheStreet) -- This week's Biotech Stock Mailbag is open for business. @adamfeuerstein @JohnCFierce They took your advice and got a savvy health care investor and you still complain? Only beer can please you. - Benjamin Hodges (@BHodge14) November 20, 2014 "They" refers to Northwest Biotherapeutics , which raised another $35 million in two separate deals announced earlier this week.

Adam on Biotech Stocks — I was waiting for that moment when my work writing about new drugs and my daughter's love of Japanese anime would cross over. Today's that day, thanks to Abbvie. From the creative geniuses deep inside Abbvie's marketing department comes brands names for the company's two, new hepatitis C drugs: Exviera Viekirax Drug name or Pokemon?

Royalty Pharma's $3.3 Billion Transaction is Bullish for Vertex Pharma — Stocks in this article: VRTX The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.

Clovis Lung Cancer Update Swings Momentum to Rival, Slightly — BOULDER, Col. ( TheStreet) -- Clovis Oncology and AstraZeneca are locked in a tight and very competitive race to develop two similar, targeted lung cancer drugs. Healthcare investors are watching closely, naturally. On Wednesday, a somewhat disappointing clinical update from Clovis swung momentum every so slightly in AstraZeneca's direction.

Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells — CAMBRIDGE, Mass. ( TheStreet) -- A second experimental drug from Agios Pharmaceuticals designed to attack the "metabolism" of cancer cells has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia. Of 14 patients with acute myeloid leukemia (AML) evaluable for response, seven patients achieved an objective response to treatment with four escalating doses of the Agios drug known as AG-120.

NeoStem's Stem Cell Therapy Fails Mid-Stage Heart Attack Study — Stocks in this article: NBS Inject a cocktail of undifferentiated stem cells into a patient who has suffered a heart attack, and days or even weeks later, the stem cells transform into cardiac cells and rebuild the damaged heart muscle. Months later, the patient has a "new" healthy heart.

Adam on Biotech Stocks — How Two Math Geeks Explain Celldex's Life-Extending Brain Tumor Therapy What you're looking at above is a graphical representation of the overall survival benefit demonstrated by an experimental cancer immunotherapy ("vaccine") called rindopepimut developed by Celldex Therapeutics.

Amicus Drug Improves Marker of Heart Health in Fabry Patients — PHILADELPHIA ( TheStreet) -- Fabry disease patients treated with Amicus Therapeutics' experimental pill migalastat exhibited improvements in the size of their hearts and fewer disease-related events compared to similar patients treated with currently approved injectable therapies. The new migalastat data compliment earlier results from a successful phase III study announced in August.

Celldex Immunotherapy Prolongs Survival for Recurrent Brain Tumor Patients — HAMPTON, NJ ( TheStreet) -- Treatment with an experimental, targeted immunotherapy developed by Celldex Therapeutics added to Roche's Avastin is delaying tumor growth and extending survival in patients with a certain type of recurrent brain tumor, according to interim results from a mid-stage study presented Friday at a medical meeting.

Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind — BOSTON ( TheStreet) -- This week's Biotech Stock Mailbag opens with an email from Mike A. regarding Spectrum Pharmaceuticals . "Will you do a piece on Spectrum Pharmaceuticals' Captisol-enabled melphalan when it files and eventually garners approval, vaulting the company into significant profitability?
More Articles →
Nov 21, 2014

@DewDiligence pump the stock higher via Twitter and CNBC? Other than that, not much.

Nov 21, 2014

$CTIC files $200M mixed shelf. Gearing up for Preferred Series 22-26.

Nov 21, 2014

$NBS can wave its hand all weekend, the study still failed. Did anyone expect a failed study to stop the company from moving forward anyway?

Nov 21, 2014

For my friends attending Financial Follies tonight, I hope you all party like Jefferies investment bankers. But no switching

Nov 21, 2014

. @BuzzFeedBen Based on the sycophantic ramblings in HuffPo and Wolff articles, reporters are supposed to shut up and pass the free wine.

Nov 21, 2014

Great tribute RT @TheStreet: .@JimCramer on His Dad: ‘Our Last Day Together Was Our Best One’

Nov 21, 2014

Friday beer note: My better half drank @JacksAbby Kiwi Rising last night and it was exceptional. Find it and enjoy.

Learn how to connect with Adam on social media by joining Muck Rack Pro

Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Share This Profile